At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,410 enrolled
Drug / intervention
Plecanatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation
In Brief
A Phase 3 clinical trial evaluating Plecanatide and Placebo for Chronic Idiopathic Constipation. Completed, enrolled 1,410 participants across 167 sites.
Detailed Summary
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Idiopathic Constipation
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedApr 2014
Primary CompletionMay 2015
Study CompletionJul 2015
TodayJul 2026
First PostedApr 24, 2014
Enrollment StartApr 1, 2014
Primary CompletionMay 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.2 years ago
Interventions
Plecanatidedrug
Placebodrug